- Home
- ULBI vs PLRX Comparison
ULBI vs PLRX Comparison
Compare ULBI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULBI
- PLRX
- Stock Information
- Founded
- ULBI 1990
- PLRX 2015
- Country
- ULBI United States
- PLRX United States
- Employees
- ULBI N/A
- PLRX N/A
- Industry
- ULBI Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ULBI Miscellaneous
- PLRX Health Care
- Exchange
- ULBI Nasdaq
- PLRX Nasdaq
- Market Cap
- ULBI 98.1M
- PLRX 90.9M
- IPO Year
- ULBI 1992
- PLRX 2020
- Fundamental
- Price
- ULBI $5.05
- PLRX $1.41
- Analyst Decision
- ULBI Strong Buy
- PLRX Hold
- Analyst Count
- ULBI 1
- PLRX 10
- Target Price
- ULBI $14.00
- PLRX $9.79
- AVG Volume (30 Days)
- ULBI 65.8K
- PLRX 734.5K
- Earning Date
- ULBI 05-09-2025
- PLRX 05-08-2025
- Dividend Yield
- ULBI N/A
- PLRX N/A
- EPS Growth
- ULBI N/A
- PLRX N/A
- EPS
- ULBI 0.31
- PLRX N/A
- Revenue
- ULBI $173,275,000.00
- PLRX N/A
- Revenue This Year
- ULBI $35.52
- PLRX N/A
- Revenue Next Year
- ULBI N/A
- PLRX N/A
- P/E Ratio
- ULBI $16.22
- PLRX N/A
- Revenue Growth
- ULBI 2.74
- PLRX N/A
- 52 Week Low
- ULBI $4.07
- PLRX $1.10
- 52 Week High
- ULBI $13.39
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- ULBI 58.57
- PLRX 39.44
- Support Level
- ULBI $4.36
- PLRX $1.36
- Resistance Level
- ULBI $4.60
- PLRX $1.72
- Average True Range (ATR)
- ULBI 0.24
- PLRX 0.11
- MACD
- ULBI 0.11
- PLRX 0.04
- Stochastic Oscillator
- ULBI 85.86
- PLRX 13.89
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.